Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic cancer. We have recently carried out a pharmacogenomic study in cancer patients treated with gemcitabine, and found that one genetic polymorphism of an enzyme involved in gemcitabine metabolism can cause interindividual variations in the pharmacokinetics and toxicity of this agent. In this paper, we review recent genetic studies of gemcitabine, and discuss the possibility of individualised cancer chemotherapy based on a pharmacogenomic approach.
With progress in the development of anticancer agents, many cancer patients now benefit from chemotherapy. Before treatment, however, it is difficult to predict whether the selected chemotherapy will be really effective and tolerable to the patient. Therefore, considerable effort has been made to obtain information that could be used to devise tailor-made therapy. Recent progress in molecular biology has revealed that genetic factors can at least partly explain interindividual variations in the efficacy and toxicity of anticancer agents. We have recently carried out a prospective pharmacogenomic study in cancer patients treated with gemcitabine (2 0 ,2 0 -difluorodeoxycytidine, dFdC), and found that one of the single-nucleotide polymorphisms (SNPs) in the cytidine deaminase gene influences the pharmacokinetics and toxicities of this agent (Sugiyama et al, 2007) . Gemcitabine is a deoxycytidine analogue that demonstrates broad anticancer activity in various solid tumours, including pancreatic cancer and non-small-cell lung cancer (NSCLC). Because of the widespread use of gemcitabine, a better understanding of the mechanisms determining its activation, and development of resistance against it has been needed, and this has prompted active genetic studies in relation to this agent. In this review, therefore, we focus on genetic studies of gemcitabine that have yielded data potentially useful for the establishment of individualised cancer chemotherapy.
GEMCITABINE METABOLISM AND MECHANISM OF ACTION
Like cytarabine, another widely used nucleoside analogue, gemcitabine is a prodrug that requires cellular uptake and intracellular phosphorylation in order to exert its action (Figure 1 ) (Fukunaga et al, 2004; Mini et al, 2006) . Once administered, gemcitabine is transported into cells by nucleoside transporters. Gemcitabine is then phosphorylated into gemcitabine monophosphate (dFdCMP) by deoxycytidine kinase (DCK), and dFdCMP is subsequently phosphorylated to gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP) by nucleoside monophosphate (UMP/CMP) and diphosphate kinase. Gemcitabine exerts its cytotoxic effect mainly through inhibition of DNA synthesis by being incorporated into the DNA strand as the active dFdCTP. It is known that gemcitabine has a unique mechanism of action known as 'self-potentiation' (Heinemann et al, 1992) . For example, dFdCDP potently inhibits ribonucleotide reductase, resulting in a decrease of competing deoxyribonucleotide pools necessary for DNA synthesis. Again, dFdCTP suppresses inactivation of dFdCMP by inhibiting deoxycytidine monophosphate deaminase (DCTD). On the other hand, more than 90% of administered gemcitabine is converted, and thus inactivated, by cytidine deaminase (CDA) into 2 0 -deoxy-2 0 ,2 0 -difluorouridine (dFdU). Phosphorylated metabolites of gemcitabine are reduced by cellular 5 0 -nucleotidase (5 0 -NT), and dFdCMP is also converted, and inactivated, by DCTD into 2 0 -deoxy-2 0 ,2 0 -difluorouridine monophosphate (dFdUMP). This paper discusses these various metabolic pathways related to gemcitabine cellular pharmacology and DNA repair. In Table 1 , we summarise the genetic polymorphisms related to gemcitabine pathways, their allele frequencies in different ethnic groups, and the resulting functional changes. In this paper, A of the translation initiation codon ATG is numbered 1 and the first methionine of a protein is numbered 1.
(SLC29A1) and ENT2 (SLC29A2)) and three concentrative nucleoside transporters (CNTs; CNT1 (SLC28A1), CNT2 (SLC28A2), and CNT3 (SLC28A3)) (Mini et al, 2006) . Kinetic studies of human cell lines have shown that gemcitabine intracellular uptake is mediated mainly by ENT1 and, to a lesser extent, by CNT1 and CNT3.
The reported allele frequencies of nucleoside transporter gene variants are generally low except ENT1 À706 G4C in Caucasians and ENT1 À1050 G4A in Africans, as shown in Table 1 (Osato et al, 2003; Damaraju et al, 2005; Kim et al, 2006; Myers et al, 2006) . To date, it is unclear whether these genetic variants of nucleoside transporter genes including ENT1 contribute to interindividual differences in response to gemcitabine. The functional analyses of the two nonsynonymous SNPs of ENT1 (SLC29A1 647T4C and 1171G4A) and the three nonsynonymous SNPs of CNT3 (SLC28A3 14G4A, 391 C4T, and 1538A4T) failed to demonstrate functional diversity (Osato et al, 2003; Damaraju et al, 2005) . On the other hand, a recent study found that individuals with CGG/CGC haplotypes based on the three SNPs in the promoter region of ENT1 (SLC29A1 À1345C4G, À1050 G4A, À706G4C) showed 1.37-fold higher median expression of the ENT1 transcript than those with the common CGG/CGG haplotypes, suggesting that ENT1 promoter region variants may influence gene expression and alter gemcitabine chemosensitivity (Myers et al, 2006) .
As to expression, several studies have suggested that ENT1 expression of mRNA/proteins in tumour tissues may be a good predictive marker of outcome in cancer patients receiving gemcitabine. Spratlin et al (2004) performed an immunohistochemical study on paraffin-embedded tumour tissues from 21 patients with pancreatic cancer and reported that overall survival was significantly longer in those expressing detectable amounts of ENT1 in tumour blocks than in those with low or absent ENT1 following gemcitabine treatment (median, 13 months vs 4 months; P ¼ 0.01). Polymerase chain reaction analysis of 81 patients with pancreatic cancer also showed that those with high ENT1 mRNA expression in the tumour specimens had significantly longer survival after gemcitabine therapy than patients with low ENT1 levels (median, 25.7 vs 8.5 months; Po0.001) . Similar results were obtained in a study of 12 bladder cancer patients treated with gemcitabine, which demonstrated that the mean level of ENT1 mRNA in tumour specimens was significantly higher in patients achieving a complete pathological response than in those with stable disease (1.166 vs 1.021; P ¼ 0.040) . These results suggest that tumour-specific expression of ENT1 may be a promising predictive biomarker of outcome after gemcitabine treatment, although formal validation in prospective studies is needed.
CYTIDINE DEAMINASE
Cytidine deaminase is involved in the salvaging of pyrimidines, and plays a key role in detoxifying gemcitabine. Therefore, patients with impaired CDA activity might develop strong toxicities after administration of gemcitabine, while CDA overexpression in tumour tissues might reduce the antitumour efficacy of this drug. An in vitro study has demonstrated resistance to gemcitabine in cells overexpressing CDA (Neff and Blau, 1996) .
So far, two nonsynonymous SNPs, 79A4C (Lys27Gln) and 208G4A (Ala70Thr), have been identified in the coding region of the human CDA gene (Yue et al, 2003; Fukunaga et al, 2004; Gilbert et al, 2006; Sugiyama et al, 2007) . Ethnic or racial differences in the allele frequencies of these SNPs have been reported, as shown in Table 1 . Remarkable reduction in activity of 70Thr CDA was reported in vitro (Yue et al, 2003) and in vivo (Sugiyama et al, 2007) , while only marginal reduction in activity of 27Gln CDA was observed in vitro (Yue et al, 2003; Gilbert et al, 2006) . On the other hand, Fitzgerald et al (2006) investigated SNPs in the promoter region of CDA in vitro and in vivo, and found that some promoter CDA haplotypes might affect CDA activity.
With regard to the correlation between CDA SNPs and clinical outcome, we have recently carried out a prospective pharmacogenomic study in cancer patients treated with gemcitabine (Sugiyama et al, 2007) . In that study, 256 Japanese patients who had not previously received gemcitabine were enrolled. In our study, we defined the haplotype without amino-acid changes as the *1 group, and haplotypes harbouring the 79A4C and 208G4A were designated *2 and *3, respectively. The relationships between the diplotype groups and the pharmacokinetic parameters of gemcitabine are summarised in Table 2 . The data clearly showed a haplotype *3-dependent decrease in gemcitabine clearance (CL m À2 ) and increases in peak concentration (C max ) and area under the curve (AUC) values, although these parameters were not significantly influenced by haplotype *2. The values of AUC and CL m À2 observed in the patient with 208AA (*3/*3) were five-fold and one-fifth of the median of the 208GG (non*3/non*3) group, respectively ( Figure 2 ). Then, associations of haplotype *3 with toxicities were analysed. Nadir grades of neutrophil counts were compared between the patient groups with or without haplotype *3 under individual therapeutic regimens. Although there were no significant differences in the incidences of grade X3 neutropaenia between the two groups receiving gemcitabine monotherapy, grade X3 neutropaenia occurred more frequently in the group with haplotype *3 than in the group without haplotype*3 when gemcitabine was administered with carboplatin, cisplatin, or 5-fluorouracil. We concluded that haplotype *3 harbouring 208G4A decreased the clearance of gemcitabine, and increased the incidence of neutropaenia when patients were coadministered platinum-containing drugs or 5-fluorouracil. Indeed, the patient with CDA 208AA developed severe myelosuppression with severe gastrointestinal toxicities after gemcitabine plus cisplatin combination therapy (Yonemori et al, 2005) . Extra caution may be necessary if patients carrying a *3 allele, especially those who are homozygous for *3, are treated with gemcitabine. On the other hand, Vasile et al (2006) recently examined the correlation between CDA SNPs and clinical efficacy in 61 NSCLC patients treated with gemcitabine alone or gemcitabine plus cisplatin, and reported that the patients with CDA 79AA (n ¼ 21) showed a significantly better response rate and progression-free survival than those with CDA 79AC or 79CC (n ¼ 40) (response rate: 52.4 vs 20%; median progression-free survival: 8.0 vs 2.5 months; P ¼ 0.0136). Further functional and clinical studies focusing on these CDA SNPs are required.
With regard to gene expression, Ganti et al (2006) investigated the gene expression of CDA in bone marrow mononuclear cells in 71 patients with advanced solid tumours, and reported that patients with a lower relative gene expression of CDA tended to show a higher incidence of grades 2 -4 haematological toxicity during gemcitabine therapy. Recently, some additional interesting results have been reported by Bengala et al (2005) , who performed a phase I study of gemcitabine infusion at a fixed dose rate in patients with pancreatic cancer, and also investigated the relationship between CDA mRNA expression in peripheral blood mononuclear cells and clinical outcome. They reported that patients with a lower gene expression level of CDA showed significant longer overall survival than those with a higher expression level (median, 8.5 vs 3.7 months; P ¼ 0.03). On the other hand, as to expression in tumour tissues, Giovannetti et al (2006) reported that multivariate analysis failed to show any prognostic significance of CDA mRNA expression in 81 patients with pancreatic cancer receiving gemcitabine. 
DEOXYCYTIDINE KINASE
Deoxycytidine kinase is the rate-limiting enzyme for the intracellular phosphorylation of gemcitabine to its active phosphate form. Therefore, DCK may play an important role in sensitivity to gemcitabine. A clear correlation between DCK activity and gemcitabine sensitivity in tumour xenografts has been reported (Kroep et al, 2002) . Haplotype analysis in the 5 0 regulatory region (À360C4G and À201C4T) suggested that À360C/À201C and À360G/À201T had almost complete linkage disequilibrium, and a functional study revealed that patients carrying the À360CG/À201CT and À360GG/ À201TT genotypes expressed significantly higher levels of DCK mRNA than patients carrying the À360CC/À201CC genotype (Shi et al, 2004) . Then the relationship between DCK SNP haplotypes and event-free survival in 122 patients with acute myeloid leukaemia treated with cytarabine was analysed, and slight but statistically significant prolongation of event-free survival time in the group with À360CG/À201CT and À360GG/À201TT over the group with À360CC/À201CC (2-year event-free survival rate, 30.7 vs 23.2%; P ¼ 0.0423) was observed. Recently, Joerger et al (2006) detected two nonsynonymous SNPs in a Caucasian population, 364C4T (Pro122Ser) and 727A4C (Lys243Gln), but their clinical relevance has not yet been clarified.
Recent clinical studies have also shown an association between tumoral DCK expression level and clinical outcome. Sebastiani et al (2006) investigated the relationship between the clinical outcome of pancreatic cancer patients treated with gemcitabinebased chemotherapy and immunohistochemical expression of DCK in cancer tissues. They reported that patients whose tumours showed low DCK expression (n ¼ 9) had significantly shorter overall survival than those whose tumours showed high expression (n ¼ 23) (median, 14.6 vs 21.7 months; Po0.009). They also sequenced the entire DCK-encoding gene in 17 human pancreatic cancer cell lines and nine samples of cancer tissue from patients, but no mutations were identified. Mey et al (2006) administered gemcitabine intravesically to 12 patients with bladder cancer, and reported that the mean expression of mRNA in the tumours was significantly higher in patients who achieved a complete pathological response than in those who did not. On the other hand, Seve et al (2005) reported that immunohistochemical expression of DCK protein in tumours was not significantly correlated with the survival of NSCLC patients treated with gemcitabine-based chemotherapy.
5
0 -NUCLEOTIDASE Since phosphorylated metabolites of gemcitabine are reduced by cellular 5 0 -NT, the activity level of 5 0 -NT may be one of the factors affecting the clinical outcome of gemcitabine therapy. Using malignant cells obtained from 43 NSCLC patients receiving gemcitabine-based chemotherapy, Seve et al (2005) applied immunohistochemical methods to assess the abundance of proteins involved in gemcitabine pathways, including cN-II, one of the cytosolic nucleotidases that have been shown to be predictive factors in patients with acute myeloid leukaemia (AML) receiving cytarabine. They reported that cN-II was expressed in 86% of the patients, and that among various proteins investigated, only the level of cN-II was significantly correlated with overall survival (P ¼ 0.02). Since low levels of cN-II were associated with a poor prognosis in NSCLC patients receiving gemcitabine and with a better prognosis in AML patients receiving sytrabine (Seve et al, 2005) , further studies are necessary to confirm the usefulness of cN-II as a prognosis factor.
RIBONUCLEOTIDE REDUCTASE
Ribonucleotide reductase is the rate-limiting enzyme of the DNA synthesis pathway and converts ribonucleoside diphosphate to deoxyribonucleoside diphosphate, which is essential for DNA synthesis and repair. Ribonucleotide reductase consists of two 
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H Ueno et al subunits, ribonucleotide reductase M1 (RRM1) and ribonucleotide reductase M2 (RRM2). Kwon et al (2006) investigated the association between polymorphisms of RRM1 and gemcitabine chemosensitivity in vitro using 62 human cancer cell lines. When the association between these SNPs and gemcitabine IC 50 was examined, only cell lines with RRM1 2232G4A showed a tendency to be more chemosensitive to gemcitabine, although none of the differences reached a statistically significant level. Bepler et al (2005) analysed the RRM1 promoter for polymorphism, and discovered two SNPs, RRM1 À37C4A and À524T4C. There was a strong linkage between these SNPs, and À37CC in combination with À524TT was the most frequently observed allelotype, accounting for 42.4% of the ethnically diverse population of 1129. They investigated RRM1 promoter allelotypes and the outcomes of patients who had undergone surgical resection for NSCLC. It was found that patients with the À37CC/À524TT allelotype had better overall and disease-free survival than patients with the À37AC/À524CT allelotype (median overall survival, 80 vs 46 months; P ¼ 0.06, median disease-free survival, 74 vs 36 months; P ¼ 0.03). However, no association between allelotype and tumoral RRM1 expression was found. Rosell et al (2004b) examined the potential correlation of RRM1 mRNA expression in specimens of NSCLC resected from 67 patients who had been treated with neoadjuvant gemcitabine/platinum. They found a good correlation between RRM1 expression in tumours and survival: significant differences in median survival were observed between the 17 patients in the bottom quartile of RRM1 expression and the 15 in the top quartile (median, 52 vs 26 months; P ¼ 0.018). They also reported similar results in patients with advanced NSCLC treated with gemcitabine/cisplatin therapy (Rosell et al, 2004a) . Patients with low RRM1 mRNA expression levels had significantly longer median survival than those with high levels (median, 13.7 vs 3.6 months; P ¼ 0.009). Bepler et al (2006) also reported that increased RRM1 expression resulted in resistance to gemcitabine both in vitro and clinically. They found that the gemcitabine IC 50 of lung cancer cell lines with increased RRM1 expression was higher than that of cell lines with decreased RRM1 expression, and the results they obtained in a prospective phase II clinical trial in patients with advanced NSCLC showed a significant inverse correlation between RRM1 expression and disease response to gemcitabine and carboplatin therapy (P ¼ 0.002 and r ¼ À0.498). Therefore, tumoral RRM1 expression may be a useful marker of outcome in NSCLC patients receiving gemcitabine-based chemotherapy.
With regard to RRM2, the association between its genetic polymorphisms and resistance to gemcitabine has not been reported. Duxbury et al (2005) demonstrated an association of RRM2 overexpression with gemcitabine chemoresistance in pancreatic adenocarcinoma cells: the gemcitabine IC 50 was four times higher in RRM2 recombinant than with an empty vector (Po0.05). Goan et al (1999) selected a gemcitabine-resistant cell line KB-GEM (IC 50 ¼ 32 mM) from human oropharyngeal epidermoid carcinoma KB cells (IC 50 ¼ 0.3 mM), and found that RRM2 mRNA (nine-fold) and protein (two-fold) were overexpressed in KB-GEM in comparison with the parental KB cells.
DEOXYCYTIDYLATE DEAMINASE AND UMP/CMP KINASE
Gemcitabine monophosphate is inactivated to dFdUMP by DCTD. A few SNPs including a nonsynonymous one, DCTD 172A4G (Asn58Asp), have been reported (Table 1; Fukunaga et al, 2004; Gilbert et al, 2006) . Recombinant Asp58 DCTD was reported to have 11% of wild-type activity for dFdCMP. dFdCMP is further phosphorylated to dFdCDP by UMP/CMP kinase, which is ubiquitously present in human tissues (van Rompay et al, 1999) . To date, neither association of genetic polymorphisms nor expression of either DCTD or UMP/CMP kinase with clinical outcome of gemcitabine treatment has been demonstrated.
DNA REPAIR
As the main mechanism of action of gemcitabine is potent inhibition of DNA synthesis, DNA repair may play an important role in gemcitabine-mediated cell death. Recently, Li et al (2006) investigated 13 SNPs of eight DNA damage response and repair genes in 92 patients with resectable pancreatic cancer treated with neoadjuvant gemcitabine-based chemotherapy. They found that RecQ1 1596(*6), Rad54L 2190C4T, and ATM IVS20-77 T4C genotypes had a significant effect on overall survival. The strongest genetic effect on survival was observed for RecQ1 1596(*6), with median overall survival times of 18.9 and 13.1 months for the AC and CC genotypes, respectively, compared with a mean survival time of 46.9 months for the AA wild type (P ¼ 0.001). De las Penas et al (2006) investigated the association of survival with genetic polymorphisms of various DNA repair genes in 135 cisplatin/gemcitabine-treated NSCLC patients at stage IIIB and IV. After adjusting for performance status, a significantly low hazard ratio (0.44) for carriers of XRCC3 722TT (241Met/Met) compared to carriers of 722CT (241Thr/Met) was demonstrated (P ¼ 0.01). With regard to the expression levels of DNA repair genes, Lord et al (2002) investigated the relationship between excision repair cross-complementing group 1 ERCC1 expression in tumours with response or overall survival in NSCLC patients treated with cisplatin/gemcitabine. They failed to show any significant association between ERCC1 expression and response, but reported that low expression of ERCC1 in tumours was associated with longer survival (61.6 vs 20.4 weeks in the low and high expression groups, respectively). Bepler et al (2006) also found a similar trend for the relationship between ERCC1 expression and NSCLC response. Cytotoxic synergism has been demonstrated between gemcitabine and cisplatin through downregulation of ERCC1 activity by gemcitabine (Lord et al, 2002) .
CONCLUSION AND FUTURE DIRECTIONS
In this article, we have reviewed recent genetic studies of gemcitabine. The impact of genetic polymorphisms as well as tumour-specific expression of mRNA/proteins on gemcitabine efficacy and toxicity has been described. Looking at these data, tumour-specific expression of ENT1, RRM1 or ERCC1, or some DNA repair genetic polymorphisms appear to be promising indicators of prognosis in patients receiving gemcitabine chemotherapy, although prospective pharmacogenetic-based clinical studies will be necessary to clarify the usefulness of these biomarkers in patients receiving gemcitabine-based chemotherapy. With regard to adverse reactions caused by gemcitabine, the expression level or genetic polymorphism of CDA seems to be a good predictor. SNP, CDA 208A4G, or CDA expression level may be candidate biomarkers for individualised gemcitabine-based chemotherapy to avoid severe toxicity, at least in Japanese and some African populations in which considerable numbers of homozygote carriers exist, as is the case for UGT1A1*28 for irinotecan and TPMT genotypes for thiopurine drugs.
